Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
DPAGT1-CDG is a form of congenital disorders of N-linked glycosylation characterized by hypotonia, intractable seizures, developmental delay, microcephaly and severe fetal hypokinesia. Additional features that may be observed include apnea and respiratory deficiency, cataracts, joint contractures, vermian hypoplasia, dysmorphic features (esotropia, arched palate, micrognathia, finger clinodactyly, single flexion creases) and feeding difficulties. The disease is caused by loss-of-function mutations in the gene DPAGT1 (11q23.3).
Data assembled from 7 of 12 sources · Last updated Sep 21, 2026, 4:53 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about DPAGT1-congenital disorder of glycosylation
Features include always present findings: Hypsarrhythmia, Low muscle tone (hypotonia), Infantile spasms, and Single transverse palmar crease and others; and sometimes findings: Flexion contracture, Hypoproteinemia, Aggressive behavior, and Elevated circulating hepatic transaminase concentration and others. 29 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Seizure, Aggressive behavior, Intellectual disability |
Muscles | 3 | Flexion contracture, Low muscle tone (hypotonia), Generalized hypotonia |
Eyes | 2 | Cataract, Nystagmus |
Digestive system | 2 | Elevated circulating hepatic transaminase concentration, Jaundice |
Lungs and breathing | 2 | Difficulty breathing (respiratory insufficiency), Apnea |
Lab test results | 1 | Elevated circulating hepatic transaminase concentration |
Head and neck | 1 | Microcephaly |
Skin | 1 | Skin dimple |
Arms and legs | 1 | Clinodactyly of the 5th finger |
DPAGT1 encodes dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 (408 aa). UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. Highest expression in Cells Cultured fibroblasts (50.3 TPM) and Cervix Endocervix (43.7 TPM).
DPAGT1-congenital disorder of glycosylation is caused by mutations in the DPAGT1 gene on chromosome 11.
The DPAGT1 protein participates in DPAGT1 T234Hfs*116, Defective DPAGT1 causes CDG-1j, CMSTA2, and Defective DPAGT1 does not transfer GlcNAc to DOLP pathways.
DPAGT1 is classified as a druggable target (Enzyme category) with score 5.8.
Genetic testing for DPAGT1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for DPAGT1-congenital disorder of glycosylation has been reported in the published literature.
Phenotype severity distribution: 9 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for DPAGT1-congenital disorder of glycosylation.
202 publications have been identified in PubMed for DPAGT1-congenital disorder of glycosylation. Kisho has analyzed 147 by research type. Research spans Review / Meta-Analysis (46%), Basic Science / Preclinical (43%), and Diagnostic / Biomarker (3%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 68 | 46% |
Laboratory research | 63 | 43% |
Testing and diagnosis research | 5 | 3% |
Disease patterns and progression | 5 | 3% |
Patient case studies | 3 | 2% |
New treatment approaches | 2 | 1% |
Other research | 1 | 1% |
Yi L (2026). [PMID: 41264770](https://pubmed.ncbi.nlm.nih.gov/41264770/). *Protein Cell*. [Review / Meta-Analysis]
Zhu N (2026). [PMID: 41177858](https://pubmed.ncbi.nlm.nih.gov/41177858/). *Sci China Life Sci*. [Basic Science / Preclinical]
Tachida Y (2026). [PMID: 41917388](https://pubmed.ncbi.nlm.nih.gov/41917388/). *Adv Exp Med Biol*. [Review / Meta-Analysis]
Ding S (2026). [PMID: 41939861](https://pubmed.ncbi.nlm.nih.gov/41939861/). *Front Immunol*. [Review / Meta-Analysis]
He M (2026). [PMID: 41685570](https://pubmed.ncbi.nlm.nih.gov/41685570/). *Int J Mol Med*. [Review / Meta-Analysis]
Johannes L (2026). [PMID: 41173705](https://pubmed.ncbi.nlm.nih.gov/41173705/). *Trends Cell Biol*. [Review / Meta-Analysis]
Damiano C (2026). [PMID: 41554119](https://pubmed.ncbi.nlm.nih.gov/41554119/). *J Inherit Metab Dis*. [Basic Science / Preclinical]
Ünsal Y (2026). [PMID: 39975416](https://pubmed.ncbi.nlm.nih.gov/39975416/). *J Clin Res Pediatr Endocrinol*. [Review / Meta-Analysis]
Liu X (2025). [PMID: 40531880](https://pubmed.ncbi.nlm.nih.gov/40531880/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Li Y (2025). [PMID: 40609958](https://pubmed.ncbi.nlm.nih.gov/40609958/). *Biochim Biophys Acta Mol Cell Res*. [Basic Science / Preclinical]